Interleukin (IL)-15 plays a major role in accumulation of unique CD16(À) natural killer (NK) cells in the human endometrium, partly via selective extravasation of peripheral blood (PB) counterparts from local microvascular circulation. While IL-15 exhibits a chemotactic activity for PB CD16(À) NK cells, IL-15 attenuates their binding capacity to dermatan sulfate, the major CD62L ligand expressed on human uterine microvascular endothelial cells (HUtMVECs). These findings suggest that premature action of IL-15 interferes with CD62L-dependent tethering/rolling of PB CD16(À) NK cells on HUtMVECs, which is an early critical process of leukocyte extravasation. In this study, we investigated the mechanisms underlying the IL-15 regulation in the initial CD62L-dependent contact between PB CD16(À) NK cells and HUtMVECs. Unlike other candidate molecules, recombinant IL-15 downregulated CD62L expression on freshly isolated PB CD16(À) NK cells. IL-12 and IL-10, the two known upregulators of CD62L on CD16(À) NK cells, were not detectable in HUtMVECs and endometrial perivascular stromal cells. Binding to immobilized dermatan sulfate increased surface IL-15 receptor-alpha chain expression on CD16(À) NK cells. Under ovarian steroid stimulation, IL-15 was detectable on the surface, but not in the supernatant, of cultured HUtMVECs. Ovarian steroid-induced IL-15 expression on HUtMVECs was not attenuated by chondroitinase ABC (which degrades chondroitin sulfate-A and -C and dermatan sulfate) or sodium acetate buffer (which dissociates cytokines from their cognate receptors). These results suggest that HUtMVECs secrete a less soluble form of IL-15 into local microcirculation. Instead, HUtMVECs bear a membrane-bound form IL-15 under the influence of ovarian steroids, which may be favorable for preventing downregulation of CD62L on PB CD16(À) NK cells and facilitating their initial contact with HUtMVECs.
INTRODUCTION
An unusual leukocyte subpopulation of CD16(À) natural killer (NK) cells infiltrates the stromal areas of the human cycling endometrium [1, 2] . The density of endometrial CD16(À) NK cells fluctuates across the menstrual cycle; it is low in the proliferative phase, but sharply rises after ovulation during the early to midsecretory phase. These NK cells are shed with other endometrial cells during menstruation, whereas their number further increases in the decidualizing endometrium when embryo implantation occurs [3, 4] . Studies support the idea that the postovulatory rise of endometrial NK cells, at least in part, results from selective extravasation of circulating peripheral blood (PB) CD16(À) NK cells [5] [6] [7] . One of the key molecules involved in this event is interleukin (IL)-15, a cytokine/chemokine that is uniquely expressed in the human endometrium [8] [9] [10] .
When leukocytes egress from circulation into tissues, they undergo sequential multistep interactions with local vascular endothelial cells. These leukocyte-endothelial interactions consist of weak-to-intermittent leukocyte bonding onto endothelial cells (tethering/rolling), reciprocal cell activation/tight adhesion, and leukocyte crawling/transendothelial migration [11] . Both human uterine microvascular endothelial cells (HUtMVECs) and PB CD16(À) NK cells have the molecular machinery required for each step on their cell surface [12] [13] [14] . For instance, CD62L is an adhesion molecule essential for leukocyte tethering/rolling. CD62L is expressed more densely on PB CD16(À) NK cells compared with other leukocyte subsets [15, 16] . In addition, PB CD16(À) NK cells express a unique combination of chemokine receptors, including CCR5, CCR7, CXCR3, and IL-15 receptor-a chain (IL-15Ra), which are essential for reciprocal leukocyte-endothelial activation [17, 18] . Meanwhile, HUtMVECs bear the functional ligands for both CD62L (dermatan sulfate proteoglycans versican, biglycan, and serglycin) and these chemokine receptors (CCL4, CCL19, CCL21, CXCL9, and IL-15). The expression level of these molecules in HUtMVECs is upregulated in vivo after ovulation or in vitro following progesterone stimulation [19] [20] [21] [22] [23] [24] .
We recently found that freshly isolated PB CD16(À) NK cells bind immobilized dermatan sulfate preferentially via surface CD62L. Interestingly, short-term recombinant IL-15 pretreatment significantly reduced surface CD62L density on PB CD16(À) NK cells [15] and CD62L-dependent CD16(À) NK cell binding to the glycosaminoglycans, including dermatan sulfate [18] . These findings raise the possibility that premature action of locally produced IL-15 may impede CD62L-dependent tethering/rolling of circulating PB CD16(À) NK cells on HUtMVECs and the subsequent extravasation process.
There are several plausible explanations for the mechanisms underlying HUtMVECs regulating IL-15 action on local circulating CD16(À) NK cells. First, some molecules produced by HUtMVECs may reverse IL-15-induced downregulation of surface CD62L expression on CD16(À) NK cells. The representative candidate molecules are IL-10 and IL-12, which are the cytokines that can upregulate CD62L surface expression selectively on CD16(À) NK cells in vitro [15] . Second, soluble-form IL-15 produced by HUtMVECs may be anchored onto dermatan sulfate proteoglycans on these cells and presented only to the leukocytes that tethered/rolled on endothelial cells, as shown in the relationship between the chemokine CCL21 and dermatan sulfate proteoglycan versican [25] . Third, IL-15 may be bound to the plasma membrane of HUtMVECs and presented only to the attached leukocytes, whereas its secretion into endometrial microcirculation may be tightly controlled [26] . The aim of this study was to test these hypotheses.
MATERIALS AND METHODS

Subjects
The study was approved by the local ethical committee of Kansai Medical University. Peripheral blood (200 ml) was drawn from four male (age 25-39 yr) and five female (age 22-32 yr) healthy volunteers. The endometrial samples were obtained from seven fertile women (age 33-42 yr, three in the proliferative phase and four in the secretory phase) undergoing hysterectomy for cervical dysplasia under informed consent. They had regular menstrual cycles ranging from 25 to 32 days and did not receive any hormonal treatment.
Reagents
The reagents were obtained from Nacalai Tesque (Kyoto, Japan), unless otherwise indicated. Incubation was performed at room temperature for 30 min, unless otherwise specified.
Enrichment and Stimulation of PB NK Cell Subsets
PB mononuclear cells were isolated by centrifugation on 1.077 g/ml lymphocyte separation solution at 400 3 g for 30 min. As described previously [18] , CD16(À) and CD16(þ) NK cells were enriched twice using a MACS NK Cell Isolation Kit/anti-human CD16 Microbead (Miltenyi Biotec, Auburn, CA). The purity of each NK cell subset was confirmed to be over 95% [18] . Enriched CD16(À) and CD16(þ) NK cells were incubated with or without recombinant human IL-10 (50 ng/ml), IL-15 (10 ng/ml), CCL4 (100 nM), CCL19 (100 nM), or CXCL9 (100 nM; Peprotech, London, U.K.) at 378C for 30 min. The cells (10 7 cells per milliliter) were incubated with 20 ll fluorescent mouse antihuman CD62L monoclonal antibody (Dreg56, IgG 1 ; Biolegend, San Diego, CA) or control antibody (Biolegend) for 15 min.
Flow Cytometry
After being washed, cells were analyzed with FACS Caliber (BD Biosciences, San Jose, CA), and the mean fluorescent intensity (MFI) was calculated using CellQuest software (BD Biosciences). The MFI ratio was defined as the MFI of the target molecule divided by the MFI of the control antigen.
NK Cell Binding Assay to Immobilized Dermatan Sulfate
Dermatan sulfate (1 mg/ml; Seikagaku Kogyo Corp., Tokyo, Japan) was coated overnight onto flat-bottom 96-well plates at 48C, followed by incubation with 20% fetal calf serum for 2 h. The cell suspension of enriched NK cells (10 5 cells) was inoculated to the wells and allowed to bind for 30 min with 120 rpm rotation. The wells were filled with 10% fetal calf serum supplemented with 20 mM HEPES, 0.14 M NaCl, 1 mM CaCl 2 , and 1 mM MgCl 2 (pH 7). The plate was then inverted for 10 min. The wells were gently aspirated to remove unbound cells. The cells that bound to the wells were retrieved and resuspended in 20% fetal calf serum. The cells were then incubated for 15 min with fluorescent mouse monoclonal antibodies against human CCR5 (T21/8, IgG 1 ), CCR7 (TG8, IgG 2a ), CXCR3 (TG1, IgG 1 ), or IL-15Ra (JM7A4, IgG 2b ; Biolegend), or with control antibody. After being washed, cells were analyzed with flow cytometry, as described above.
Western Blot Analysis
A portion of the endometrial samples was homogenized in lysis buffer containing protease inhibitors (2 lM aprotinin, 50 lM leupeptin, 125 lM bestatin, and 25 lM pepstatin A). The solubilized fraction was preserved at À808C until use, electrophoresed on a polyacrylamide gel, and electrotransferred to a polyvinylidene difluoride membrane. The membrane was incubated with 5% nonfat milk in Tris-buffered saline containing 0.1% Tween-20 to reduce nonspecific antibody binding. The membrane was then incubated for 30 min with 0.5 lg/ml mouse monoclonal antihuman IL-12 IgG 1 antibody (MAB219; R&D Systems, Minneapolis, MN) or goat polyclonal antihuman IL-10 IgG antibody (AF-217-NA; R&D Systems), or control antibody. After being washed in Tris-buffered saline, the membrane was incubated with a secondary antibody conjugated with horseradish peroxidase (1:10 000 dilution; Santa Cruz Biotechnology, Santa Cruz, CA). After being washed again, the immunoreactivity was detected with an ECL Plus detection kit (Amersham-Pharmacia, Uppsala, Sweden).
Immunohistochemistry
The remaining endometrial samples were fixed in paraformaldehyde, embedded in paraffin, and cut into 4-lm sections. After being deparaffinized in limonene (Falma, Inc., Tokyo, Japan) and rehydrated in a graded series of ethanol, the sections were immersed in 3% hydrogen peroxide for 5 min to quench endogenous peroxidase and then in 10% fetal calf serum for 10 min to minimize subsequent nonspecific antibody binding. In a moist chamber, the sections were incubated overnight at 48C with 2 lg/ml MAB219 (for IL-12), AF-217-NA (for IL-10), or control antibody. After being washed in PBS, the immunoreactivity was detected using an LSAB Kit (Dako, Kyoto, Japan).
Culture of HUtMVECs and Detection of IL-15
As described previously, HUtMVECs (Cambrex, Walkersville, MD) were pooled and maintained in phenol red-free medium 199 supplemented with 0.03 M HEPES, 10% charcoal-stripped fetal calf serum, 100 IU/ml penicillin, 100 lg/ml streptomycin, and 2.5 lg/ml amphotericin B at 378C in humidified 5% CO 2 [18] . The cells (10 5 cells per milliliter) from the two passages were cultured further with or without 10 À7 M progesterone and/or 10 À9 M 17b-estradiol dissolved in dimethylsulfoxide for 24 h. IL-15 in the culture supernatant was quantified using a Quantikine ELISA Kit (R&D Systems). The cells were treated at 378C with 0.2 IU/L chondroitinase ABC (Sigma-Aldrich, St. Louis, MO) for 60 min to degrade chondroitin sulfate-A and -C and dermatan sulfate, or with 0.05 M acid sodium acetate buffer (pH 4.5) for 20 min to dissociate cytokines from their cognate receptors. The cells were incubated for 15 min with 2 lg/ml mouse monoclonal antihuman IL-15 IgG 1 antibody (MAB2471; R&D Systems) or control antibody. After being washed, the cells were then incubated with fluorescent goat antimouse IgG (Biolegend) for 15 min. After being washed, cells were analyzed using flow cytometry.
Statistics
The data sets were compared using a two-sided paired t-test, Dunnett test, Pearson chi square test, or Fisher exact test using Statcel (OMS, Tokorozawa, Japan). The data following Gaussian distribution were shown as mean 6 SD. P , 0.05 was regarded as significantly different.
RESULTS
IL-15
Attenuates Surface CD62L Expression on PB CD16(À) NK Cells CCL4, CCL19, CXCL9, and IL-15 are the known chemoattractants for PB CD16(À) NK cells that are expressed in HUtMVECs. We compared the effect of these chemokines on surface CD62L expression of MACS-enriched CD16(À) and CD16(þ) NK cells (n ¼ 5; Fig. 1 ). Enriched CD16(À) NK cells expressed CD62L on the cell surface at a significantly higher rate (93.1% 6 2.9%; P ¼ 0.000021) and MFI ratio (29.6 6 12.5; P ¼ 0.00073) compared with CD16(þ) NK cells (expression rate 3.8% 6 1.0%, MFI ratio 2.8 6 0.6). Without stimulation, both CD16(À) NK cells and CD16(þ) NK cells KITAYA AND YASUO maintained surface CD62L expression status (CD16(À) NK cells: P . 0.24, rate 88.8% 6 2.9%, ratio 27.1 6 11.9; CD16(þ) NK cells: rate 3.3% 6 0.9%, ratio 2.9 6 0.5). Recombinant IL-10 was used for a positive control, as this cytokine was shown to upregulate surface CD62L expression on CD16(À) NK cells [15] . IL-10, however, did not significantly (P . 0.10) affect CD62L expression status on CD16(À) NK cells (rate 94.3% 6 4.2%, ratio 29.4 6 8.3) and CD16(þ) NK cells (rate 2.9% 6 0.8%, ratio 3.1 6 0.7) in our experimental setting. In addition, recombinant CCL4, CCL19, or CXCL9 had no significant (P . 0.52) effects on surface CD62L expression of CD16(À) NK cells (CCL4: rate 86.3% 6 4.3%, ratio 22.8 6 6.9; CCL19: rate 84.6% 6 5.3%, ratio 18.1 6 5.6; CXCL9: rate 86.1% 6 3.3%, ratio 23.4 6 6.4) or CD16(þ) NK cells (CCL4: rate 2.7% 6 1.0%, ratio 2.6 6 0.5; CCL19: rate 2.8% 6 0.5%, ratio 3.0 6 0.4; CXCL9: rate 3.3% 6 0.7%, ratio 2.9 6 0.5). By contrast, recombinant IL-15 significantly (P , 0.0078) reduced the CD62L expression on CD16(À) NK cells (rate 69.1% 6 7.7%, ratio 6.2 6 3.5) compared with nonstimulated cells. The effect of IL-15 on CD62L of CD16(À) NK cells was detectable at a concentration of 10 ng/ml or more (n ¼ 2). Meanwhile, recombinant IL-15 did not affect CD62L expression (P . 0.78; rate 3.2% 6 0.8%, ratio 3.0 6 0.5) on CD16(þ) NK cells.
Lack of IL-10 and IL-12 Expression in Microvascular Endothelial Cells in Human Cycling Endometrium
We investigated the expression and localization of IL-10 and IL-12, two known upregulators of CD62L density on freshly isolated PB CD16(À) NK cells in vitro [15] (Fig. 2) . By Western blotting analysis, the immunoreactivity for IL-10, but not for control IgG, was detected in the solubilized fraction of six endometrial samples examined (three in the proliferative phase, three in the secretory phase) as a single band at a molecular weight of 35-36 kDa. The results indicate that IL-10 protein is present as a noncovalently linked homodimer in the endometrium, as reported in other human tissues [27] . However, the immunoreactivity for IL-12 was not detectable by Western blotting or immunohistochemistry in any endometrial sample examined, indicating the absence of IL-12 protein in the intact human endometrial tissues. By immunohistochemistry, homogenous immunostaining for IL-10 was detected in surface epithelial cells and glandular epithelial cells throughout the menstrual cycle. In addition, focal punctate immunostaining for IL-10 was detectable in some stromal cells at all phases in the menstrual cycle, but not in microvascular endothelial cells or perivascular stromal cells. There were no marked cycle-dependent or individual-dependent variances in immunostaining pattern for IL-10. 
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Binding to Dermatan Sulfate Increases IL-15Ra and CXCR3 Expression on PB CD16(À) NK Cells
Freshly isolated PB CD16(À) NK cells were shown to express a combination of surface chemokine receptors that is unique to this subset (CCR5, CCR7, CXCR3, and IL-15Ra) [17] . To mimic the status of PB CD16(À) NK cells undergoing tethering/rolling on HUtMVECs, we examined the expression change of these chemokine receptors on PB CD16(À) NK cells after in vitro binding to immobilized dermatan sulfate under shear stress (n ¼ 5; Fig. 3 ). CCR7 was expressed brightly (ratio ¼ 14.4 6 4.9) on the majority (rate ¼ 92.1% 6 2.6%) of freshly isolated PB CD16(À) NK cells. CXCR3 expression on these NK cells showed the bimodal (bright or negative) pattern (rate ¼ 32.2% 6 10.6%, ratio ¼ 3.6 6 1.7). Meanwhile, CCR5 (rate ¼ 55.0% 6 5.6%, ratio ¼ 5.5 6 1.4, data not shown) and IL-15Ra (rate ¼ 39.4% 6 7.4%, ratio ¼ 4.3 6 1.5) were expressed dimly or were absent on these NK cells. Binding to immobilized dermatan sulfate did not affect CCR5 expression status (data not shown; P . 0.47; rate ¼ 53.4% 6 4.2%, ratio ¼ 4.8 6 1.0), but significantly decreased CCR7 expression (P ¼ 0.0044; rate ¼ 68.3% 6 9.2%, ratio ¼ 4.8 6 2.4) on CD16(À) NK cells. By contrast, binding to dermatan sulfate significantly increased the expression of CXCR3 (P ¼ 0.0014; rate ¼ 77.0% 6 9.8%, ratio ¼ 9.4 6 2.7) and IL-15Ra (P ¼ 0.00022; rate ¼ 79.3% 6 14.2%, ratio ¼ 29.5 6 8.7) on these NK cells.
Ovarian Steroids Stimulate Surface IL-15 Expression but Not IL-15 Secretion by Cultured HUtMVECs
Using an in vitro culture system, we examined the effect of the ovarian steroids on IL-15 secretion and surface IL-15 expression (Fig. 4) by HUtMVECs (n ¼ 4). Soluble IL-15 was detected in the cell supernatant in only one well (5.9 pg/ml) out of four independent experiments in the control culture. Soluble IL-15 was below the detectable level (2 pg/ml) in the supernatant of the cells cultured with 17b-estradiol. Meanwhile, soluble IL-15 was detected in two wells out of four independent experiments in the supernatant of the cells cultured with progesterone alone (4.3 pg/ml and 2.8 pg/ml) or in combination with 17b-estradiol (3.2 pg/ml and 2.8 pg/ml).
IL-15 was detectable marginally on the surface of primary HUtMVECs (rate ¼ 3.7% 6 0.7%, ratio ¼ 1.2 6 0.1) and control culture cells (rate ¼ 2.1% 6 1.3%, ratio ¼ 1.1 6 0.2). By contrast, stimulation with 17b-estradiol significantly enhanced the surface IL-15 expression on HUtMVECs (P ¼ 0.0083; rate 10.5% 6 3.6%, ratio 2.7 6 0.5), as did progesterone (P ¼ 0.0037; rate 11.7% 6 4.2%, ratio 4.0 6 0.5). The effect of progesterone on the IL-15 MFI ratio was greater than that of 17b-estradiol, whereas the effect on the IL-15 expression rate was similar between these two ovarian steroids (P ¼ 0.56). The effect on IL-15 expression on HUtMVECs was maximal when the cells were stimulated with the combination of 17b-estradiol and progesterone (P ¼ 
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0.00012; rate 27.4% 6 6.9%, ratio 8.5 6 0.8). These ovarian steroid-stimulated surface IL-15-positive HUtMVECs (rate 18.3% 6 5.1%, ratio 4.8 6 1.3, n ¼ 3) were challenged with chondroitinase ABC, which is the degrading enzyme for chondroitin sulfate-A and -C and dermatan sulfate, or acid sodium acetate buffer, which elutes cytokines that are bound to their cognate receptors (Fig. 5) . These treatments did not significantly alter surface IL-15 expression on HUtMVECs (P . 0.33; without treatment: rate 15.3% 6 5.8%, ratio 4.3 6 0.8; following chondroitinase ABC treatment: rate 17.2% 6 6.7%, ratio 4.2 6 1.1; following acid sodium acetate buffer treatment: rate 14.3% 6 5.1%, ratio 4.2 6 0.7).
DISCUSSION
In this study, we disclosed that short-term stimulation with recombinant IL-15 significantly reduces the expression level of CD62L on the surface of freshly isolated PB CD16(À) NK cells. While long-term culture with recombinant IL-15 induced the internalization of surface CD62L expression on memory T cells [28] , our findings implicate that CD62L on CD16(À) NK cells is able to respond to IL-15 stimulation more quickly.
IL-10 and IL-12 are the cytokines that are capable of inducing surface CD62L expression on freshly isolated PB CD16(À) NK cells [15] . Consistent with previous studies [29, 30] , IL-10 was detectable in epithelial cells, but not in microvascular endothelial cells or perivascular stromal cells, in the human cycling endometrium. Judging by the expression status and localization pattern, IL-10 is unlikely to be involved in regulation of surface CD62L expression on PB CD16(À) NK cells in endometrial microcirculation. Moreover, IL-12 was not expressed in any endometrial samples examined.
Cross-linking of CD62L on human PB T cells with its specific ligands or agonistic antibodies has been shown to upregulate surface expression of CXCR4, but not that of CCR5 or CCR7 [31] . We observed that in vitro binding to dermatan sulfate enhances the surface CXCR3 and IL-15Ra expression on PB CD16(À) NK cells, whereas it decreased CCR7 expression on these NK cells without affecting CCR5 expression. The findings implicate that engagement of CD62L with the glycosaminoglycan side chains of proteoglycans on HUtMVECs plays an important role in modulation of chemokine receptor expression on the surface of these NK cells.
Without stimulation, HUtMVECs scarcely secreted IL-15 or expressed it on their cell surface. While 17b-estradiol and/or progesterone did not affect IL-15 secretion by HUtMVECs, these ovarian steroids markedly increased their surface IL-15 expression. The findings suggest that HUtMVECs bear IL-15 on their surface under the influence of the ovarian steroids, but secrete low levels of IL-15 into local microcirculation. These IL-15 are unlikely to be presented on the glycosaminoglycan side chains of the cell surface proteoglycans on HUtMVECs, as enzymatic digestion of chondroitin sulfate-A or -C or dermatan sulfate did not affect its surface expression level. Additionally, acid acetate treatment did not cleave surface IL-15, indicating that IL-15 is not attached to IL-15Ra on HUtMVECs, but is an integral membrane-bound form IL-15 that was previously identified on monocytes [26] and decidual cells in the first trimester pregnancy [9] .
Taken together, these results provide a potential reciprocal interaction model between HUtMVECs and circulating PB CD16(À) NK cells. 
